Previous 10 | Next 10 |
ATLANTA, GA - ( NewMediaWire ) - March 28, 2024 - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its Chief Scientific Officer, Mark Newman, PhD, will present data on GEO-...
ATLANTA, GA, March 12, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that its Chairman and CEO, David Dodd, will present at the 36t...
GeoVax Labs (NASDAQ: GOVX) , is a clinical-stage biotech company committed to developing safe and effective vaccines and immunotherapies against cancers and infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin(...
Manufacturing Process for Phase 3 and Commercial Production Being Developed for GeoVax MVA-Based Vaccines ATLANTA, GA - ( NewMediaWire ) - March 06, 2024 - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectio...
Progress across the pipeline in multiple clinical trials, including Phase 2 program of GEO-CM04S1, next-generation Covid-19 vaccine, and multicenter Phase 1/2 study of Gedeptin ® , targeting advanced head and neck cancer Catalyst-rich 2024 with data readouts p...
Evolv Technologies Holdings Inc. (EVLV) is expected to report $-0.14 for Q4 2023 The Lion Electric Company (LEV) is expected to report $-0.1 for Q4 2023 Fisker Inc. Class A (FSR) is expected to report $-0.2 for Q4 2023 Y-mAbs Therapeutics Inc. (YMAB) is expected to report $-0.19 for Q...
ATLANTA, GA - ( NewMediaWire ) - February 19, 2024 - Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that its Chairman and CEO, David Dodd, will present at the 2024 BIO CEO & Investor Con...
Intellectual Property Assets Strengthened for Cancer Immunotherapy Program and for Marburg Virus and HIV Vaccines ATLANTA, GA - ( NewMediaWire ) - February 13, 2024 - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vacci...
Results Demonstrate Potential Protective Immunity Against Multiple SARS-CoV-2 Variants ATLANTA, GA, Feb. 06, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against ca...
2024-01-29 09:18:44 ET More on GeoVax GeoVax Labs, Inc. (GOVX) Q3 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on GeoVax Historical earnings data for GeoVax Financial information for GeoVax Read the full article on Seeking Alpha...
News, Short Squeeze, Breakout and More Instantly...
GeoVax Labs Inc. Company Name:
GOVX Stock Symbol:
OTCMKTS Market:
Tesla CEO Elon Musk does not seem to agree with Republicans at least on one thing. On Wednesday, the billionaire, true to his credentials as a tech...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, GA - ( NewMediaWire ) - May 07, 2024 - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it will report first quarter...